JP2025505200A - Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法 - Google Patents

Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法 Download PDF

Info

Publication number
JP2025505200A
JP2025505200A JP2024546424A JP2024546424A JP2025505200A JP 2025505200 A JP2025505200 A JP 2025505200A JP 2024546424 A JP2024546424 A JP 2024546424A JP 2024546424 A JP2024546424 A JP 2024546424A JP 2025505200 A JP2025505200 A JP 2025505200A
Authority
JP
Japan
Prior art keywords
groups
alkyl
optionally substituted
independently selected
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505200A5 (https=
Inventor
ティモシー ジェイ. センター,
レスリー エー. デーキン,
エレナ ドルギフ,
ジェシカ エイチ. オルセン,
アキラ ジェイ. シミズ,
スティーブン ディー. ストーン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2025505200A publication Critical patent/JP2025505200A/ja
Publication of JP2025505200A5 publication Critical patent/JP2025505200A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024546424A 2022-02-08 2023-02-08 Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法 Pending JP2025505200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307933P 2022-02-08 2022-02-08
US63/307,933 2022-02-08
PCT/US2023/012579 WO2023154310A1 (en) 2022-02-08 2023-02-08 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Publications (2)

Publication Number Publication Date
JP2025505200A true JP2025505200A (ja) 2025-02-21
JP2025505200A5 JP2025505200A5 (https=) 2026-02-04

Family

ID=85570218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546424A Pending JP2025505200A (ja) 2022-02-08 2023-02-08 Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法

Country Status (7)

Country Link
US (1) US20250163021A1 (https=)
EP (1) EP4476199A1 (https=)
JP (1) JP2025505200A (https=)
CN (1) CN118984821A (https=)
AU (1) AU2023219516A1 (https=)
CA (1) CA3251230A1 (https=)
WO (1) WO2023154310A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) * 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) * 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
JP5406722B2 (ja) * 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン1受容体モジュレータとしての置換されたスルホンアミド誘導体
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
CN106749330A (zh) * 2016-12-29 2017-05-31 长春海谱润斯科技有限公司 一种杂环衍生物及使用该杂环衍生物的有机发光器件
US20220144838A1 (en) * 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
IL296423A (en) * 2020-04-22 2022-11-01 Anima Biotech Inc Collagen 1 translation inhibitors and methods of use thereof
CN115867532A (zh) * 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途

Also Published As

Publication number Publication date
AU2023219516A1 (en) 2024-08-22
CA3251230A1 (en) 2023-08-17
US20250163021A1 (en) 2025-05-22
EP4476199A1 (en) 2024-12-18
CN118984821A (zh) 2024-11-19
WO2023154310A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
JP2025505200A (ja) Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法
EP3788039B1 (en) Factor xiia inhibitors
US4758568A (en) Quinoline therapeutic agents
JP2024544060A (ja) Apol1のスピロ環式阻害剤およびこれを使用する方法
US12612379B2 (en) Inhibitors of APOL1 and methods of using same
JP2025505644A (ja) Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法
JP2025505645A (ja) Apol1の阻害剤としてのスピロピペリジン誘導体およびその使用方法
CA3179333A1 (en) Modulators of alpha-1 antitrypsin
CN114127054B (zh) 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物
WO2021013832A1 (en) 1-(6-(methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway diseases
AU2022246108A1 (en) Indoline derivatives as ddr1 and ddr2 inhibitors
OA21973A (en) 4-Phenyl-2-(1H-1,2,3-Triazol-4-YL) Piperidin-4-OL derivatives as inhibitors Of APOL1 and methods of using same.
CN118574809A (zh) 作为apol1抑制剂的4-苯基-2-(1h-1,2,3-三唑-4-基)哌啶-4-醇衍生物和其使用方法
AU2024301644A1 (en) Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity
EA053250B1 (ru) Производные 4-фенил-2-(1h-1,2,3-триазол-4-ил)пиперидин-4-ола в качестве ингибиторов apol1 и способы их применения
HK40048874A (en) Factor xiia inhibitors
HK40048874B (en) Factor xiia inhibitors
TW201514162A (zh) 作爲鉀離子通道抑制劑之呔
CN105878243A (zh) 吡非尼酮衍生物在制药中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260127